DexCom, Inc. (DXCM)

Check out top investors' recommendation for DXCM
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
91.29
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments. The company’s in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joanne Wuensch BMO Capital Markets Buy   Sep 08, '17     90.00  Sep 08, '18  N/A 
Raj Denhoy Jefferies & Co. Buy   Aug 22, '17     91.00  Aug 22, '18  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Aug 16, '17     87.00  Aug 16, '18  N/A 
Chris Cooley Stephens Inc. Buy   Aug 02, '17     83.00  Aug 02, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Aug 02, '17     92.00  Aug 02, '18  N/A 
Raj Denhoy Jefferies & Co. Buy   Jul 13, '17     91.00  Jul 13, '18  N/A 
Joanne Wuensch BMO Capital Markets Buy   Jul 12, '17     105.00  Jul 12, '18  N/A 
Joanne Wuensch BMO Capital Markets Buy   May 25, '17     105.00  May 25, '18  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   May 22, '17     78.00  May 22, '18  N/A 
William Plovanic Canaccord Genuity Buy   May 03, '17     90.00  May 03, '18  N/A 
Ben Andrew William Blair & Company, L.L.C. Buy   Apr 27, '17       Apr 27, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Feb 21, '17       Feb 21, '18  N/A 
William Plovanic Canaccord Genuity Buy   Jan 23, '17     95.00  Jan 23, '18  N/A 
Chris Cooley Stephens Inc. Buy   Jan 13, '17     75.00  Jan 13, '18  N/A 
Michael Weinstein JPMorgan Buy   Jan 13, '17       Jan 13, '18  N/A 
Sean Lavin Lazard Capital Markets Buy   Jan 13, '17     92.00  Jan 13, '18  N/A 
Steven Lichtman Oppenheimer & Co. Buy   Jan 13, '17       Jan 13, '18  N/A 
Richard Lau Wedbush Securities Inc. Buy   Jan 11, '17     85.00  Jan 11, '18  N/A 
William Plovanic Canaccord Genuity Buy   Dec 21, '16       Dec 21, '17  N/A 
William Plovanic Canaccord Genuity Buy   Nov 02, '16     70.00  Nov 02, '17  N/A 
< previous1234